

Forbion co-leads €72 Million Series A Financing in Complement Therapeutics to Advance Novel Therapies Targeting Complement-Mediated Diseases

- *Forbion co-led round alongside GIMV, BGV, CIC, Panakes, Hadean and Seroba*
- *Series A round comes just one year after raising €5 million seed funding in February 2022*
- *Funding to support further development of lead asset for treatment of Geographic Atrophy (late dry age-related macular degeneration)*
- *Complement Therapeutics is part of Forbion Ventures Fund V which focuses on building and enabling companies to develop new therapeutics that can impact the future of medicine*

Naarden, The Netherlands – x April 2023 - Forbion, a leading European life sciences venture capital firm, today announces that it has co-led a €72 million Series A financing round in Complement Therapeutics GmbH (CTx). This financing round is a fast follow-on round to the initial €5M Series Seed which was co-led by Forbion and its joint venture partner BioGeneration Ventures (BGV) in February 2022.

Both Forbion and BGV are known for their company building capabilities, including those based on university or pharma spin-outs and completely *de novo* inception of new biotech companies. CTx was initially spun out of The University of Manchester by BGV, based on its innovative science, strong intellectual property and distinguished academic founders. It was then further built by Forbion and BGV together into a leading European biotech company focusing on complement-mediated diseases.

"We are delighted with the rapid progress made by Complement Therapeutics in the last twelve months. Patients impacted by complement-mediated diseases, such as macular degeneration, chronic renal disease and diseases of the neurological system, often have to cope with debilitating symptoms throughout their lifetime, and this can lead to a significant burden not only on them, but also their families. We look forward to continuing to support the company as it drives forward a pipeline of novel assets addressing these unmet needs in complement-mediated diseases" said **Dr Dmitrij Hristodorov, Partner, Forbion.**

"With a potentially highly differentiated lead asset combined with a precision medicine approach, we are excited by the opportunity to further develop CTx001 for the treatment of Geographic Atrophy through to the clinic." said **Dr Rafiq Hasan, CEO and Managing Director at Complement Therapeutics GmbH.** "The support of Forbion and BGV now complemented by the new syndicate enables us to generate additional data demonstrating CTx001's unique and

differentiated mechanism of action, with the potential to transform the treatment landscape in geographic atrophy.”

With this new round of financing, CTx will continue the development and complete a Phase Ib clinical proof of concept of its lead product CTx001. CTx001 is a highly innovative AAV gene therapy for the treatment of Geographic Atrophy (GA) secondary to dry age-related macular degeneration (dry-AMD). Additionally, proceeds from this financing will be deployed to grow its laboratory-based activities in Stevenage (UK), evaluate CTx’s pipeline assets for non-ocular indications as well as further develop the novel Complement Precision Medicine (CPM) platform.

-Ends-

For more information please contact:

Forbion and BGV

Laura Asbjornsen

Head of Communications

Email: laura.asbjornsen@forbion.com

About Forbion

Forbion (www.forbion.com) is a dedicated life sciences venture capital firm with offices in The Netherlands, Germany and Singapore. Forbion invests in life sciences companies that are active in the (bio-) pharmaceutical space. Forbion manages well over €2.3 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. Forbion’s current team consists of over 30 life sciences investment professionals that have built an impressive performance track record since the late nineties with successful investments in 95 companies. The firm is a signatory to the United Nations Principles for Responsible Investment. Besides financial objectives, Forbion selects investments that will positively affect the health and well-being of patients. Its investors include the EIF, through its European Recovery Programme (ERP), LfA, Dutch Venture Initiative (DVI), AMUF and EFSI facilities and KfW Capital through the Programme, “ERP – Venture Capital Fonds investments”. Forbion operates a joint venture with BioGeneration Ventures (BGV), the manager of seed and early-stage funds.

About Complement Therapeutics GmbH

Complement Therapeutics GmbH (CTx) is a German headquartered early-stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases. The Company is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade.

Our lead investigational product (CTx001) is being evaluated as a potential gene therapy for GA, a leading cause of blindness. Additional programs will evaluate potential therapeutic opportunities in other complement-mediated conditions.

The Company is also developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform, to enable the quantification of over 30 complement cascade proteins enabling more precise diagnosis and monitoring of disease.

The Company has subsidiaries in the UK (Complement Therapeutics Ltd) and in the USA (Complement Therapeutics Inc) as well as research laboratories in Stevenage, UK.